芦可替尼治疗骨髓纤维化：越早越好？
Ruxolitinib for myelofibrosis: The earlier, the better?
作者信息
Bose Prithviraj, Vachhani Pankit
机构信息
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Department of Medicine, Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
出版信息
Cancer. 2024 Dec 15;130(24):4224-4226. doi: 10.1002/cncr.35592. Epub 2024 Oct 13.
Abstract
There is mounting evidence to support the use of ruxolitinib earlier in the disease course of MF. Use in intermediate-1 risk MF is generally associated with higher efficacy and lower toxicity.
摘要
越来越多的证据支持在骨髓纤维化（MF）病程中更早地使用芦可替尼。在中危-1风险的MF中使用通常与更高的疗效和更低的毒性相关。
相似文献
1
Ruxolitinib for myelofibrosis: The earlier, the better?芦可替尼治疗骨髓纤维化：越早越好？
Cancer. 2024 Dec 15;130(24):4224-4226. doi: 10.1002/cncr.35592. Epub 2024 Oct 13.
2
Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary.芦可替尼对骨髓纤维化患者的早期治疗与延迟治疗：通俗易懂的总结
Future Oncol. 2025 Mar;21(6):617-625. doi: 10.1080/14796694.2024.2440255. Epub 2024 Dec 18.
3
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.骨髓纤维化的早期干预及其对结局的影响：COMFORT-I 和 COMFORT-II 研究的汇总分析。
Cancer. 2023 Jun 1;129(11):1681-1690. doi: 10.1002/cncr.34707. Epub 2023 Feb 25.
4
Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis.芦可替尼治疗的伴有或不伴有贫血的骨髓纤维化患者的治疗模式及医疗资源利用情况：一项真实世界分析
Ann Hematol. 2025 Mar;104(3):1605-1616. doi: 10.1007/s00277-025-06279-0. Epub 2025 Mar 12.
5
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.在 3b 期扩展准入 JUMP 研究中，分析骨髓纤维化患者对芦可替尼反应的预测因素。
Leuk Lymphoma. 2021 Apr;62(4):918-926. doi: 10.1080/10428194.2020.1845334. Epub 2020 Nov 19.
6
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.芦可替尼停药后的情况：218 例骨髓纤维化患者停药原因、疾病阶段的影响和结局。
Cancer. 2020 Mar 15;126(6):1243-1252. doi: 10.1002/cncr.32664. Epub 2019 Dec 20.
7
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.莫米松替比 versus 持续芦可替尼或 JAK 抑制剂治疗经验的骨髓纤维化伴贫血患者的最佳可用治疗：SIMPLIFY-2 的亚组分析。
Adv Ther. 2024 Sep;41(9):3722-3735. doi: 10.1007/s12325-024-02928-4. Epub 2024 Jul 11.
8
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy.超越骨髓纤维化中芦可替尼的失败：二线治疗的演进策略。
Expert Opin Pharmacother. 2023 Jun;24(9):1091-1100. doi: 10.1080/14656566.2023.2213435. Epub 2023 May 29.
9
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.芦可替尼治疗对 COMFORT-I 研究中骨髓纤维化相关症状和其他患者报告结局的影响：一项随机、双盲、安慰剂对照试验。
J Clin Oncol. 2013 Apr 1;31(10):1285-92. doi: 10.1200/JCO.2012.44.4489. Epub 2013 Feb 19.
10
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.COMFORT-II研究中鲁索替尼联合促红细胞生成素刺激剂用于骨髓纤维化患者：一项评估鲁索替尼与最佳可用疗法治疗骨髓纤维化疗效和安全性的开放标签3期研究。
Exp Hematol Oncol. 2015 Sep 15;4:26. doi: 10.1186/s40164-015-0021-2. eCollection 2015.
本文引用的文献
1
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.芦可替尼治疗 595 例中危-1 级骨髓纤维化患者的临床结局：RUX-MF 真实世界研究。
Cancer. 2024 Dec 15;130(24):4257-4266. doi: 10.1002/cncr.35489. Epub 2024 Jul 30.
2
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.突变 JAK2 等位基因负担减少对真性红细胞增多症和原发性血小板增多症的临床影响。
Am J Hematol. 2024 Aug;99(8):1550-1559. doi: 10.1002/ajh.27400. Epub 2024 Jun 6.
3
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.芦可替尼与最佳可用疗法治疗不耐受或对羟基脲耐药的真性红细胞增多症的随机试验。
J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1.
4
Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.芦可替尼获批用于骨髓纤维化 10 年后：临床疗效评价。
Leuk Lymphoma. 2023 Jun;64(6):1063-1081. doi: 10.1080/10428194.2023.2196593. Epub 2023 Apr 20.
5
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.Ruxolitinib 在血细胞减少性骨髓纤维化中的疗效、毒性、停药和结局。
Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18.
6
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.骨髓纤维化的早期干预及其对结局的影响：COMFORT-I 和 COMFORT-II 研究的汇总分析。
Cancer. 2023 Jun 1;129(11):1681-1690. doi: 10.1002/cncr.34707. Epub 2023 Feb 25.
7
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.骨髓增殖性肿瘤临床实践指南（第 3 版）. 2022 年 NCCN
J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062. doi: 10.6004/jnccn.2022.0046.
8
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.血细胞减少表型在纤维化前期与明显原发性骨髓纤维化中的差异预后影响
Blood Cancer J. 2022 Aug 12;12(8):116. doi: 10.1038/s41408-022-00713-6.
9
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.外周血blasts 与慢性髓性白血病患者对 ruxolitinib 的反应和结局相关。
Cancer. 2022 Jul 1;128(13):2449-2454. doi: 10.1002/cncr.34216. Epub 2022 Apr 1.
10
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.预测芦可替尼治疗骨髓纤维化患者 6 个月后生存的预后模型。
Blood Adv. 2022 Mar 22;6(6):1855-1864. doi: 10.1182/bloodadvances.2021006889.
Zotero 插件